Where you inject matters: new study tests insulin at three sites
NCT ID NCT07257627
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study looked at how a single dose of the insulin drug THDB0206 behaves when injected into the upper arm, abdomen, or thigh. Twenty-seven healthy Chinese adults each received the same dose at all three sites in a random order. The goal was to see if the injection site changes how fast and how much insulin enters the blood and how it affects blood sugar levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- THDB0206 (insulin lispro)
- What this could lead to
- If successful, this study could help determine the best injection site for THDB0206, potentially improving how quickly and consistently the insulin works.
- What could go wrong
- This is a very early Phase 1 study in only 27 healthy people, so results may not apply to patients with diabetes. The study is already completed, so no new data is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
Sichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates